JAKARTA - After COVID-19 crisis subsides, PT Itama Ranoraya Tbk (IRRA) tries to keep its business afloat by expanding into durable medical devices, which are projected to generate stable income in the long run.

As explained during 2023 Annual Public Expose of Itama Ranoraya held virtually today (20/12), IRRA will expand varieties of its products to durable, long-term utilisation machine, especially for radiology and critical care segment.

"We will establish a new business line and expand to imaging, radiotherapy, and hemodialysis devices," said Dodi Nurzani, Director of IRRA. The devices include mammography equipment, C-arms, bone densitometer, linear accelerator, and hemodialysis equipment.

In order to purchase those new equipment, IRRA has set the capex to IDR 320 billion. "It will generate a positive, stable, long-term effect in our income, because the contract of these durables usually take effect annually," explained Nanan Meinanta Lasahido, Director of IRRA.

Lasahido also confirmed that the source of the capex comes from bank loans. For context, IRRA's cash and cash equivalent as of September was down to only IDR 15 billion.

"For these durable products, we aim to market them to key users across indonesia, particularly class A and B hospitals," added Satria Mulia Chaeruddin, GM of Marketing of IRRA.

As of now, key users of IRRA reach 1,765 across Indonesia, and its porducts are distrbuted by 261 distribution network points spanning from Sumatra to papua. "Next, we will expand this network and also open new branch offices in strategic cities," concluded Heru Firdausi Syarif, President Director of IRRA. (ZH)